The U.S Food & Drug Administration has granted approval for a targeted therapy called CABOMETYX ® to treat pancreatic ...

Medically reviewed by Marla Anderson, MD Stomach cancer—or gastric cancer—occurs when cells in the lining of the stomach wall ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

Clinical Director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute. “This FDA approval marks a meaningful ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...